VISEN SHANGHAI
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
VISEN Pharmaceuticals announced that the Phase 3 PaTHway China Trial of Palopegteriparatide achieved primary and key secondary endpoints in the treatment of adults with hypoparathyroidism 2024-08-12 21:00
VISEN Announces Acceptance of a Biologics License Application for Lonapegsomatropin in China 2024-03-08 10:00
Once-Weekly TransCon™ CNP Achieved Primary Efficacy Objective in ACcomplisH China Phase 2 Trial 2023-11-16 22:00
1